Akero Therapeutics IncNASDAQ:AKRO
- LAST PRICE18.7550
- TODAY'S CHANGE (%)0.4350 (2.3745%)
- Bid / Lots18.7200/ 3
- Ask / Lots18.7900/ 2
- Open / Previous Close18.6500 / 18.3200
- Day Range
- 52 Week Range
- Volume419,720
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AKRO |
|---|---|---|
| 09:32 ET | 29936 | 18.55 |
| 09:34 ET | 2773 | 18.585 |
| 09:36 ET | 5674 | 18.535 |
| 09:38 ET | 25920 | 18.32 |
| 09:39 ET | 600 | 18.33 |
| 09:41 ET | 400 | 18.2443 |
| 09:43 ET | 6584 | 18.43 |
| 09:45 ET | 416 | 18.57 |
| 09:48 ET | 1445 | 18.535 |
| 09:50 ET | 3845 | 18.55 |
| 09:52 ET | 2988 | 18.63 |
| 09:54 ET | 200 | 18.68 |
| 09:56 ET | 1565 | 18.58 |
| 09:57 ET | 100 | 18.595 |
| 09:59 ET | 1400 | 18.7 |
| 10:01 ET | 514 | 18.67 |
| 10:03 ET | 3872 | 18.56 |
| 10:06 ET | 3540 | 18.33 |
| 10:08 ET | 2528 | 18.43 |
| 10:10 ET | 1633 | 18.39 |
| 10:12 ET | 1588 | 18.42 |
| 10:14 ET | 2405 | 18.43 |
| 10:15 ET | 200 | 18.425 |
| 10:17 ET | 2578 | 18.66 |
| 10:19 ET | 2841 | 18.535 |
| 10:21 ET | 2941 | 18.4 |
| 10:24 ET | 2200 | 18.34 |
| 10:26 ET | 2167 | 18.31 |
| 10:28 ET | 2600 | 18.11 |
| 10:30 ET | 1700 | 18.03 |
| 10:32 ET | 3413 | 18.26 |
| 10:33 ET | 1564 | 18.36 |
| 10:35 ET | 21566 | 18.56 |
| 10:37 ET | 5084 | 18.58 |
| 10:39 ET | 4761 | 18.55 |
| 10:42 ET | 1300 | 18.535 |
| 10:44 ET | 2811 | 18.525 |
| 10:46 ET | 10329 | 18.64 |
| 10:48 ET | 100 | 18.64 |
| 10:50 ET | 1294 | 18.83 |
| 10:51 ET | 3224 | 18.94 |
| 10:53 ET | 3108 | 18.85 |
| 10:55 ET | 500 | 18.9 |
| 10:57 ET | 400 | 18.9661 |
| 11:00 ET | 2455 | 18.84 |
| 11:02 ET | 2144 | 18.865 |
| 11:04 ET | 400 | 18.88 |
| 11:06 ET | 600 | 18.89 |
| 11:08 ET | 2164 | 18.98 |
| 11:09 ET | 2107 | 18.91 |
| 11:11 ET | 2724 | 18.925 |
| 11:13 ET | 5863 | 18.88 |
| 11:15 ET | 500 | 19 |
| 11:18 ET | 1974 | 19.01 |
| 11:20 ET | 964 | 19.06 |
| 11:22 ET | 3900 | 19 |
| 11:24 ET | 200 | 19 |
| 11:26 ET | 963 | 18.96 |
| 11:27 ET | 1100 | 19.04 |
| 11:29 ET | 200 | 19.035 |
| 11:31 ET | 6868 | 19.115 |
| 11:33 ET | 100 | 19.115 |
| 11:36 ET | 100 | 19.11 |
| 11:38 ET | 759 | 19.115 |
| 11:40 ET | 500 | 19.13 |
| 11:42 ET | 708 | 19.16 |
| 11:45 ET | 1603 | 19.14 |
| 11:47 ET | 1193 | 19.1382 |
| 11:49 ET | 700 | 19.13 |
| 11:51 ET | 1000 | 19.16 |
| 11:54 ET | 300 | 19.19 |
| 11:56 ET | 200 | 19.18 |
| 11:58 ET | 1300 | 19.22 |
| 12:00 ET | 2668 | 19.17 |
| 12:02 ET | 3673 | 19.065 |
| 12:03 ET | 1400 | 19.07 |
| 12:05 ET | 5008 | 19.14 |
| 12:07 ET | 7144 | 19.08 |
| 12:09 ET | 7392 | 19.025 |
| 12:14 ET | 1200 | 19.12 |
| 12:16 ET | 6022 | 19.14 |
| 12:18 ET | 1692 | 19.1 |
| 12:20 ET | 6964 | 19.1 |
| 12:21 ET | 866 | 19.06 |
| 12:25 ET | 1200 | 19.09 |
| 12:27 ET | 600 | 19.14 |
| 12:30 ET | 8591 | 19.04 |
| 12:32 ET | 1200 | 18.96 |
| 12:34 ET | 974 | 18.9 |
| 12:38 ET | 1972 | 18.88 |
| 12:41 ET | 910 | 18.89 |
| 12:43 ET | 510 | 18.92 |
| 12:45 ET | 1052 | 18.89 |
| 12:48 ET | 300 | 18.9 |
| 12:50 ET | 500 | 18.88 |
| 12:52 ET | 129 | 18.885 |
| 12:54 ET | 200 | 18.885 |
| 12:56 ET | 974 | 18.905 |
| 12:57 ET | 211 | 18.9 |
| 12:59 ET | 500 | 18.91 |
| 01:01 ET | 1690 | 18.88 |
| 01:03 ET | 922 | 18.8172 |
| 01:06 ET | 872 | 18.84 |
| 01:08 ET | 400 | 18.84 |
| 01:10 ET | 700 | 18.87 |
| 01:14 ET | 500 | 18.915 |
| 01:15 ET | 904 | 18.89 |
| 01:17 ET | 478 | 18.92 |
| 01:19 ET | 400 | 18.935 |
| 01:24 ET | 2400 | 18.94 |
| 01:26 ET | 1162 | 18.92 |
| 01:28 ET | 2470 | 18.86 |
| 01:30 ET | 11957 | 18.715 |
| 01:32 ET | 870 | 18.755 |
| 01:33 ET | 500 | 18.755 |
Today
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO), from 1 hour ago by Dow Jones
1 hour ago by Dow Jones
Yesterday
NATIONALLY RANKED ROSEN LAW FIRM Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -- AKRO, from 11:33AM ET on Monday May 27, 2024 by Dow Jones
11:33AM ET on Monday May 27, 2024 by Dow JonesAKRO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges Akero Therapeutics, Inc. Investors with Losses to Contact the Firm, from 9:45AM ET on Monday May 27, 2024 by Dow Jones
9:45AM ET on Monday May 27, 2024 by Dow JonesAKRO INVESTOR DEADLINE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, from 6:05AM ET on Monday May 27, 2024 by Dow Jones
6:05AM ET on Monday May 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Akero Therapeutics Inc | 1.3B | -5.9x | --- |
Day One Biopharmaceuticals Inc | 1.2B | -5.4x | --- |
Spyre Therapeutics Inc | 1.3B | -0.5x | --- |
Pharvaris NV | 1.1B | -7.8x | --- |
Belite Bio Inc | 1.4B | -38.5x | --- |
Cullinan Therapeutics Inc | 1.4B | -7.4x | --- |
Company Information
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Contact Information
- Headquarters
- 601 Gateway Boulevard, Suite 350SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-487-6488
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Iwicki
- President, Chief Executive Officer, Director
- Andrew Cheng
- Co-Founder, Chief Operating Officer, Executive Vice President, Secretary
- Jonathan Young
- Co-Founder, Chief Scientific Officer
- Timothy Rolph
- Chief Financial Officer, Executive Vice President, Head of Corporate Development, Treasurer
- William White
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 69.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.32 |
EPS | $-3.20 |
Book Value | $9.60 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
